Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18310148 | 0.86 | CYP2C9 (0.47) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL16992177 | 0.85 | STS (0.47) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL30606462 | 0.84 | PDE4B (0.54) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL16992048 | 0.84 | PDE4B (0.54) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL17002531 | 0.84 | PDE4B (0.44) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL17002534 | 0.83 | HCRTR1 (0.45) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL16992044 | 0.83 | GPR119 (0.55) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL30606474 | 0.82 | STS (0.42) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL16992186 | 0.82 | STS (0.42) | PDE4APDE4BPDE4CPDE4DGPR119 | |
| SCHEMBL30606454 | 0.80 | LMNA (0.47) | GPR119ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-10973817-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-10973817-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3104860-B1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CASCADIAN THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-10010547-B2 | Pharmaceutical compounds | CASCADIAN THERAPEUTICS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010547-B2 | Pharmaceutical compounds | CASCADIAN THERAPEUTICS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-3104860-A1 | PHARMACEUTICAL COMPOUNDS | Cascadian Therapeutics, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | SEATTLE GENETICS, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2015120390-A1 | PHARMACEUTICAL COMPOUNDS | ONCOTHYREON INC. (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2015120390-A1 | PHARMACEUTICAL COMPOUNDS | ONCOTHYREON INC. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010547-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | PDE4A 656/4885PDE4B 508/4885PDE4C 575/4885 |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | PDE4A 656/4885PDE4B 508/4885PDE4C 575/4885 |
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | PDE4A 656/4885PDE4B 508/4885PDE4C 575/4885 |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | PDE4A 656/4885PDE4B 508/4885PDE4C 575/4885 |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | PDE4A 656/4885PDE4B 508/4885PDE4C 575/4885 |
| US-10973817-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | PDE4A 656/4885PDE4B 508/4885PDE4C 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.